|

Pharmacogenomics of Asparaginase Induced Hepatotoxicity

RECRUITINGSponsored by University of Southern California
Actively Recruiting
SponsorUniversity of Southern California
Started2018-05-22
Est. completion2026-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT03568266

Summary

This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL
* Receiving asparaginase as part of the primary treatment regimen
* Ability to understand and the willingness to sign a written informed consent
* For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC)

Exclusion Criteria:

* Patients who are unable to give informed consent

Conditions2

Acute Lymphoblastic LeukemiaCancer

Locations1 site

USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Houda Alachkar, PhD323-442-2696alachkar@usc.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.